Hybridize Therapeutics has spun out of the LUMC in 2019. Hybridize’s overarching goal is to help patients overcome untreated viral diseases by developing virus-specific RNA-based therapies, i.e. antisense oligonucleotides. They currently have a pipeline of two preclinical programs for BK-virus and SARS-CoV2 & JC-virus.
NTrans Technologies BV was founded in 2015 based on a proprietary platform technology for the intracellular delivery of bioactive molecules developed at the Hubrecht Institute of the Royal Netherlands Academy of Sciences. They are further developing this technology for both research and clinical purposes as a method for the delivery of biologicals that is safe, non-toxic, highly efficient, and easy to use.